363: What Vinay Prasad’s ouster means for biotech and the FDA
The Readout Loud
00:00
FDA Leadership Shakeup: Impacts on Biotech
This chapter examines the controversial departure of a key figure from the FDA, analyzing the political pressures and implications of their decisions on drug approvals. It discusses the challenges faced by the individual, a vocal critic of the FDA's approach, and the anticipated shifts in regulatory attitudes affecting biotech and rare disease therapies. The conversation also reflects on the broader effects of these changes on healthcare, the stock market, and the balance between stringent approvals and flexibility for innovative treatments.
Transcript
Play full episode
